― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk ...
Tuesday, the FDA lifted the clinical hold on Fulcrum Therapeutics Inc's FULC Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD). Following ...
Zacks Investment Research on MSN
FULC stock crashes as cancer risk forces its only drug program's end
Fulcrum Therapeutics FULC saw its stock crash 51.1% on Tuesday after announcing the discontinuation of its lead candidate, pociredir, for sickle cell disease (SCD). The decision effectively pushes the ...
Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results